Bolivia Medical Device Fees: The R.M. N° 0265 Tariff Framework of 2018
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The legal vehicle for device-related service fees in Bolivia is Resolución Ministerial N° 0265 (25 May 2018). The official procedures library cites it as the legal basis in the procedure for registration of imported devices, and the CADA service fee at the import stage is also charged at the tariff of that resolution. GRZAN draws a firm distinction between two kinds of number here: official fees follow the current tariff table of R.M. N° 0265 and must be looked up item by item, whereas the ranges circulating in the market, such as an official registration fee of approximately BOB 3,000 to 18,000 or a service fee of approximately USD 10,000 to 30,000, are a practical estimate rather than published values. They may be used to size a budget and must not be written into a quotation as a commitment.
The distinction is not pedantic. A tariff published in a ministerial resolution is enforceable, auditable and identical for every applicant; a range derived from market experience reflects a sample of projects and will not survive contact with a client who asks for the source. Mixing the two in a commercial document is the most common way in which a fee budget loses credibility, and it is entirely avoidable, because the authoritative document is public.
The practical rule is therefore that every figure in a Bolivian budget should carry a label: either it is traced to the current tariff table, or it is marked as a practical estimate with the basis on which it was derived.
2. Legal basis
| Regulatory instrument | Number | Publication date | Relevant provisions |
|---|---|---|---|
| Resolución Ministerial (fees and procedures) | Resolución Ministerial N° 0265 | 25 May 2018 | Full text |
| Manual para Registro Sanitario de Dispositivos Médicos | Resolución Ministerial N° 010 | As per the current version on the AGEMED website | Chapter III |
| Form 011 (application for the customs clearance authorisation certificate) | Form 011 | As per the current AGEMED version | Full text |
| Ley del Medicamento (medicines law) | Ley N° 1737 | 17 December 1996 | Article 1(e) |
Ley N° 1737 supplies the statutory basis on which fees may be charged for regulatory services, Article 1(e) being the provision cited in the official procedures library for this purpose. Resolución Ministerial N° 0265 sets the amounts and the procedural steps that attract them. Chapter III of the manual defines the registration procedure within which those fees fall due, including the point at which a resubmission becomes chargeable, and Form 011 sets the document set for the import-stage fee. A budget built from the resolution alone will be accurate on amounts and wrong on the number of times they are payable.
3. Expert insights
Insight 1: the fee resolution and the manual are companion documents, and neither is sufficient alone. The manual defines what must be submitted; R.M. N° 0265 defines how much is paid and which procedure applies. A company preparing a budget has to download both current documents. Using only one of them produces a budget that does not match the amount actually paid, either because a procedural step that attracts a fee has been omitted, or because the tariff has been superseded since the budget was drafted.
Insight 2: fees are layered, and the three layers have different natures. The first layer is official service fees under R.M. N° 0265. The second is the document chain: issue of the certificate of free sale, authentication or apostille, and certified translation into Spanish. The third is local service cost: importer, technical responsible, warehousing, technical vigilance and the administrative work that surrounds them. Only the first layer has a statutory tariff; the second and third vary widely between projects and should be estimated per project with an explicit basis.
Insight 3: rejection and resubmission repeat the official fee. Chapter III of the manual provides that a resubmission following rejection attracts a further payment. This makes the official fee a variable tied to submission quality rather than a fixed cost of entry: a file that is complete and internally consistent is charged once, while a file that is rejected and refiled is charged twice or more. Preparing the first submission thoroughly is the only reliable way to hold the official fee total down, and it is a quality investment that pays for itself in fee terms alone.
Insight 4: the fee schedule is also a planning document. Because each tariff line corresponds to a procedural step, reading the tariff backwards is a useful way to reconstruct the procedural sequence that a particular product will follow. Gaps in a project plan often appear as missing tariff lines, which is a cheaper way to find them than discovering the step when the authority requests it.
4. Practical recommendations
- Build the budget in three layers, with the official tariff looked up and entered item by item, and the other two layers estimated per project and labelled as a practical estimate.
- Assume one resubmission when setting the ceiling for official fees, while using gate checks in the dossier to reduce the probability that the assumption is realised.
- Separate official fees from service fees explicitly in quotation documents, so that a client cannot mistake a published tariff for a commercial price or the reverse.
- Re-download the tariff before each quotation, and record the version date used, so that a superseded schedule cannot be relied on later.
5. Verification checklist
- □ The current tariff table of R.M. N° 0265 has been downloaded
- □ Official fees have been looked up item by item against the specific services required
- □ Document chain costs (issue, authentication, translation) have been estimated separately
- □ The budget identifies which figures are a practical estimate
- □ The ceiling for official fees has been set on the assumption of one resubmission
Regulatory information verified as of October 29, 2026.
GRZAN supports medical device manufacturers, importers and authorised representatives with registration in Bolivia, including fee budgeting against the current R.M. N° 0265 tariff, separation of official fees from service and document chain costs, and quotation structures that distinguish published amounts from practical estimates. For assistance with a fee model or a quotation for the Bolivian market, contact the GRZAN regulatory team at info@grzanglobal.com.
GRZAN applies a writing standard of conclusions first, traceable sources and verifiable figures to its regulatory publications, and follows the tariff schedules and procedures of AGEMED and the authorities cited in this series as they are updated. For a market access plan with a fully traceable cost model for Bolivia, the team welcomes your enquiry.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us